On the impact of the CYP2D6 ultra-rapid metabolizer genotype on mirtazapine pharmacokinetics.

被引：0
|
作者：
Brockmöller, J
Kirchheiner, J
Henckel, H
Meineke, I
Roots, I
机构：
[1] Univ Gottingen, D-3400 Gottingen, Germany
[2] Humboldt Univ, D-1086 Berlin, Germany
[3] Charite Med Ctr, Berlin, Germany
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2004年 / 75卷 / 02期
关键词：
D O I：
10.1016/j.clpt.2003.11.250
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：P67 / P67
页数：1
相关论文
共 50 条
  • [1] Impact of the CYP2D6 ultra-rapid metabolizer genotype on doxepin pharmacokinetics and serotonin in platelets
    Kirchheiner, J
    Henckel, HB
    Franke, L
    Meineke, I
    Tzvetkov, M
    Uebelhack, R
    Roots, I
    Brockmöller, J
    PHARMACOGENETICS AND GENOMICS, 2005, 15 (08): : 579 - 587
  • [2] Pharmacokinetics of mirtazapine:: Enantioselective effects of the CYP2D6 ultra rapid metabolizer genotype and correlation with adverse effects
    Brockmoeller, J.
    Meineke, I.
    Kirchheiner, J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2007, 81 (05) : 699 - 707
  • [3] Are you sure the patient is a CYP2D6 ultra-rapid metabolizer?
    Gregg, Keqin
    Guo, Wenjing
    Rhodes, Robert
    Simhadri, Ashrita
    Subramanya, Archana
    Samilpa, Paul
    Langley, Lyndsey
    Ames, Kyle
    McCarty, Matt
    PHARMACOGENOMICS, 2016, 17 (16) : 1749 - 1763
  • [4] Impact of the CYP2D6 utrarapid metabolizer genotype on mirtazapine pharmacokinetics and adverse events in healthy volunteers
    Kirchheiner, J
    Henckel, HB
    Meineke, I
    Roots, I
    Brockmöller, A
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2004, 24 (06) : 647 - 652
  • [5] Impact of the CYP2D6 ultra-rapid metabolizer genotype on cis- and trans-doxepin pharmacokinetics and serotonin concentration in platelets.
    Kirchheiner, JC
    Henckel, HB
    Franke, L
    Meineke, I
    Uebelhack, R
    Roots, I
    Brockmöller, J
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2005, 77 (02) : P26 - P26
  • [6] CYP2D6 and chlorpheniramine pharmacokinetics.
    Yasuda, SU
    Zannikos, P
    Young, AE
    Fried, KM
    Wainer, JW
    Woosley, RL
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 69 (02) : P7 - P7
  • [7] CYP2D6 ultra-rapid metabolizer phenotype not associated with attempted suicide in a large sample of psychiatric inpatients
    Stephens, Dustin B.
    de Leon, Jose
    PHARMACOGENOMICS, 2016, 17 (12) : 1295 - 1304
  • [8] Impact of CYP2D6 poor metabolizer phenotype on propranolol pharmacokinetics and response
    Sowinski, KM
    Burlew, BS
    PHARMACOTHERAPY, 1997, 17 (06): : 1305 - 1310
  • [9] The CYP2C19 ultra-rapid metabolizer genotype influences the pharmacokinetics of voriconazole in healthy male volunteers
    Guo Wang
    He-Ping Lei
    Zhi Li
    Zhi-Rong Tan
    Dong Guo
    Lan Fan
    Yao Chen
    Dong-Li Hu
    Dan Wang
    Hong-Hao Zhou
    European Journal of Clinical Pharmacology, 2009, 65 : 281 - 285
  • [10] The CYP2C19 ultra-rapid metabolizer genotype influences the pharmacokinetics of voriconazole in healthy male volunteers
    Wang, Guo
    Lei, He-Ping
    Li, Zhi
    Tan, Zhi-Rong
    Guo, Dong
    Fan, Lan
    Chen, Yao
    Hu, Dong-Li
    Wang, Dan
    Zhou, Hong-Hao
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2009, 65 (03) : 281 - 285
12345